

Pharmaceutical Management Agency

Section H Update for Hospital Pharmaceuticals

Effective 1 May 2017

Cumulative for April and May 2017



Contents

Summary of decisions effective 1 May 2017	3
Section H changes to Part II	4
Index.....	9

Summary of decisions

EFFECTIVE 1 MAY 2017

- Azathioprine (Imuran) tab 25 mg and 50 mg – new listing and addition of HSS
- Azathioprine (Azamun) tab 50 mg and 50 mg – to be delisted 1 July 2017
- Calcipotriol (Daivonex) oint 50 mcg per g, 100 g – addition of HSS
- Dexamethasone phosphate (Max Health) inj 4 mg per ml, 2 ml ampoule, 10 inj pack size – new listing
- Dimethicone (healthE Dimethicone 4% lotion) lotn 4%, 200 ml – new listing and addition of HSS
- Fluphenazine decanoate (Modecate) inj 12.5 mg per 0.5 ml, inj 25 mg per ml, 1 ml and 2 ml, and 100 mg per ml, 1 ml ampoules – to be delisted 1 December 2017
- Influenza vaccine (Influvac) inj 45 mcg in 0.5 ml syringe – amended restriction
- Metronidazole (AFT) inj 5 mg per ml, 100 ml bottle – new listing
- Piperacillin with tazobactam (Tazocin EF) inj 4 g with tazobactam 0.5 g vial – new listing
- Sodium cromoglycate powder for inhalation 20 mg per dose – to be delisted 1 June 2017

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Section H changes to Part II

Effective 1 May 2017

DERMATOLOGICALS

55	DIMETHICONE (new listing and addition of HSS) Lotn 4% - 1% DV Jul-17 to 2019	4.98	200 ml	healthE Dimethicone 4% Lotion
58	CALCIPOTRIOL (addition of HSS) Oint 50 mcg per g – 1% DV Jul-17 to 2020	45.00	100 g	Daivonex

HORMONE PREPARATIONS

66	DEXAMETHASONE PHOSPHATE (new pack size) Inj 4 mg per ml, 2 ml ampoule – 1% DV Jul-16 to 2019	25.18	10	Max Health
----	--	-------	----	-------------------

Note – This is a listing of a new pack size

INFECTIONS

78	PIPERACILLIN WITH TAZOBACTAM (new listing) → Inj 4 g with tazobactam 0.5 g vial	15.50	1	Tazocin EF
86	METRONIDAZOLE (new listing) Inj 5 mg per ml, 100 ml bottle.....	1.39	1	AFT

NERVOUS SYSTEM

128	FLUPHENAZINE DECANOATE – Restricted: For continuation only (delisting) → Inj 12.5 mg per 0.5 ml ampoule	17.60	5	Modecate
	→ Inj 25 mg per ml, 1 ml ampoule.....	27.90	5	Modecate
	→ Inj 25 mg per ml, 2 ml ampoule.....			<i>e.g. Modecate</i>
	→ Inj 100 mg per ml, 1 ml ampoule.....	154.50	5	Modecate

Note – Modecate inj 12.5 mg per 0.5 ml, inj 25 mg per ml, 1 ml and 2 ml, and 100 mg per ml, 1 ml ampoules to be delisted from 1 December 2017.

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

184	AZATHIOPRINE (brand change) Tab 25 mg – 1% DV Jul-17 to 2019	9.66	100	Imuran
	Tab 50 mg – 1% DV Jul-17 to 2019	10.58	100	Imuran

Note – Azamun tab 25 mg and 50 mg to be delisted from 1 July 2017.

RESPIRATORY SYSTEM AND ALLERGIES

191	SODIUM CROMOGLYCATE (delisting) Powder for inhalation 20 mg per dose Note – Sodium cromoglycate powder for inhalation 20 mg per dose to be delisted from 1 June 2017.			
-----	---	--	--	--

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 May 2017 (continued)

VACCINES

229 INFLUENZA VACCINE (Restriction amended (affected criterion only shown))

→ Inj 45 mcg in 0.5 ml syringe
 – **0% DV Feb-17 to 31 Dec 2019** 90.00 10 **Influvac**

Restricted

Initiation — Other conditions

Any of the following Either:

- 1 Any of the following:
 - 1.1 Diabetes; or
 - 1.2 chronic renal disease; or
 - 1.3 Any cancer, excluding basal and squamous skin cancers if not invasive; or
 - 1.4 Autoimmune disease; or
 - 1.5 Immune suppression or immune deficiency; or
 - 1.6 HIV; or
 - 1.7 Transplant recipient; or
 - 1.8 Neuromuscular and CNS diseases/ disorders; or
 - 1.9 Haemoglobinopathies; or
 - 1.10 Is a child on long term aspirin; or
 - 1.11 Has a cochlear implant; or
 - 1.12 Errors of metabolism at risk of major metabolic decompensation; or
 - 1.13 Pre and post splenectomy; or
 - 1.14 Down syndrome; or
 - 1.15 Is pregnant; or
 - 1.16 Is a child aged four and under who has been hospitalised for respiratory illness or has a history of significant respiratory illness; or
- 2 Patients who are compulsorily detained long-term in a forensic unit within a DHB hospital; **or**
- 3 **People under 18 years of age living within the Seddon/Ward and rural Eastern Marlborough region (within the Nelson Marlborough District Health Board) and Kaikoura and Hurunui areas (within the Canterbury District Health Board).**

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 April 2017

BLOOD AND BLOOD FORMING ORGANS

40	SODIUM CHLORIDE (new listing) Inj 0.9%, 20 ml ampoule.....	5.00	20	Multichem
40	SODIUM CHLORIDE (HSS suspended) Inj 0.9%, 20 ml ampoule – 1% DV Mar-17 to 2019 31 Mar 2017	7.50	30	InterPharma
40	WATER (new listing) Inj 20 ml ampoule.....	5.00	20	Multichem
40	WATER (HSS suspended) Inj 20 ml ampoule – 1% DV Mar-17 to 2019 31 Mar 2017	7.50	30	Interpharma

CARDIOVASCULAR SYSTEM

44	AMIODARONE HYDROCHLORIDE (brand change) Inj 50 mg per ml, 3 ml ampoule – 1% DV Jun-17 to 2019	9.98	5	Lodi
	Note – Cordarone-X inj 50 mg per ml, 3 ml ampule to be delisted from 1 June 2017.			

GENITO-URINARY SYSTEM

61	LEVONORGESTREL (↑ price and addition of HSS) Tab 1.5 mg – 1% DV Jun-17 to 2019	4.95	1	Postinor-1
----	--	------	---	------------

HORMONE PREPARATIONS

67	PREDNISONE (addition of HSS) Tab 1 mg – 1% DV Jun-17 to 2020	10.68	500	Apo-Prednisone
	Tab 2.5 mg – 1% DV Jun-17 to 2020	12.09	500	Apo-Prednisone
	Tab 5 mg – 1% DV Jun-17 to 2020	11.09	500	Apo-Prednisone
	Tab 20 mg – 1% DV Jun-17 to 2020	29.03	500	Apo-Prednisone
68	CLOMIFENE GLOMIPHENE CITRATE (chemical name change) Tab 50 mg	29.84	10	Mylan Clomiphene Serophene

INFECTIONS

81	FUSIDIC ACID (addition of HSS) → Tab 250 mg – 1% DV Jun-17 to 2020	34.50	12	Fucidin
90	DARUNAVIR (↓ price and addition of HSS) → Tab 400 mg – 1% DV Jun-17 to 2020	335.00	60	Prezista
	→ Tab 600 mg – 1% DV Jun-17 to 2020	476.00	60	Prezista

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 April 2017 (continued)

MUSCULOSKELETAL SYSTEM

99	AURANOFIN - Restricted: for continuation only (restriction added and delisting) Tab 3 mg Note – Auranofin tab 3 mg to be delisted from 1 September 2017.			
99	LEFLUNOMIDE (brand change) Tab 10 mg – 1% DV Jun-17 to 2020 2.90 Tab 20 mg – 1% DV Jun-17 to 2020 2.90 Note – Arava tab 10 mg and 20 mg to be delisted from 1 June 2017.	30 30		Apo-Leflunomide Apo-Leflunomide
108	NAPROXEN (amended pack size) Tab long-acting 750 mg – 1% DV Jun-15 to 2018 5.60 Tab long-acting 1 g – 1% DV Jun-15 to 2018 6.53 Note – Naproxen tab 750 mg and 1 g pack size change from 90 pack bottle to 28 blister pack. The 90 tablet packs will be delisted at a later date.	28 28		Naprosyn SR 750 Naprosyn SR 1000

NERVOUS SYSTEM

109	BENZTROPINE BENZTROPINE MESYLATE (chemical name change) Tab 2 mg 7.99 Inj 1 mg per ml, 2 ml ampoule 95.00	60 5		Benztrop Cogentin
117	VENLAFAXINE (brand change) Cap 37.5 mg – 1% DV Jun-17 to 2020 6.38 Cap 75 mg – 1% DV Jun-17 to 2020 8.11 Cap 150 mg – 1% DV Jun-17 to 2020 11.16 Note – Arrow-Venlafaxine XR tab modified release 37.5 mg, 75 mg, 150 mg and 225 mg, and Efexor XR cap modified release 37.5 mg, 75 mg and 150 mg to be delisted from 1 June 2017.	84 84 84		Enlafax XR Enlafax XR Enlafax XR
123	APREPITANT (new listing) → Cap 40 mg 71.43	5		Emend
123	SUMATRIPTAN (brand change) Tab 50 mg – 1% DV Jun-17 to 2019 24.44 Tab 100 mg – 1% DV Jun-17 to 2019 46.23 Note – Arrow-Sumatriptan tab 50 mg and 100 mg to be delisted from 1 June 2017.	100 102 100 102		Apo-Sumatriptan Apo-Sumatriptan Apo-Sumatriptan Apo-Sumatriptan
124	GRANISETRON (delisting) Tab 1 mg – 1% DV Jan-15 to 2017 5.98 Note – Granirex tab 1 mg to be delisted from 1 October 2017.	50		Granirex
134	BUPROPION HYDROCHLORIDE (addition of HSS) Tab modified-release 150 mg – 1% DV Jun-17 to 2020 11.00	30		Zyban

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 April 2017 (continued)

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

142	ERLOTINIB (amended restriction – amended criteria shown only)			
	→ Tab 100 mg.....	764.00	30	Tarceva
	→ Tab 150 mg.....	1,146.00	30	Tarceva
	Restricted			
	Initiation			
	<i>Re-assessment required after 4 months</i>			
	All of the following:			
	1 Patient has locally advanced or metastatic, unresectable, non-squamous Non-Small Cell Lung Cancer (NSCLC); and			
	2 There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase; and			
	3 Either Any of the following:			
	3.1 Patient is treatment naive; or			
	3.2 Both:			
	3.2.1 Patient has documented disease progression following treatment with first line platinum based chemotherapy; and			
	3.2.2 Patient has not received prior treatment with gefitinib; or			
	3.2.3 Both:			
	3.2.13.3.1 The patient has discontinued gefitinib within 12 weeks of starting treatment due to intolerance; and			
	3.2.23.3.2 The cancer did not progress while on gefitinib; and			
	4 Erlotinib is to be given for a maximum of 3 months.			

SPECIAL FOODS

211	PROTEIN SUPPLEMENT (delisting)			
	→ Powder 5 g protein, 0.67 g carbohydrate and 0.6 g fat per 6.6 g, 275 g can			e.g. <i>Promod</i>
	Note – Promod powder to be delisted from 1 April 2017.			
213	AMINO ACID FORMULA (WITHOUT ISOLEUCINE, LEUCINE AND VALINE) (delisting)			
	→ Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can			e.g. <i>MSUD Maxamaid</i>
	Note – MSUD Maxamaid to be delisted from 1 May 2017.			

Index

Pharmaceuticals and brands

A	
Amino acid formula (without isoleucine, leucine and valine)	8
Amiodarone hydrochloride.....	6
Apo-Leflunomide.....	7
Apo-Prednisone	6
Apo-Sumatriptan.....	7
Aprepitant	7
Auranofin	7
Azathioprine	4
B	
Benzatropine mesylate	7
Benztrop	7
Benztropine mesylate	7
Bupropion hydrochloride	7
C	
Calcipotriol.....	4
Clomifene citrate	6
Clomiphene citrate	6
Cogentin	7
D	
Daivonex.....	4
Darunavir	6
Dexamethasone phosphate.....	4
Dimethicone.....	4
E	
Emend	7
Enlifax XR	7
Erlotinib	8
F	
Fluphenazine decanoate	4
Fucidin.....	6
Fusidic acid.....	6
G	
Granirex	7
Granisetron	7
H	
healthE Dimethicone 4% Lotion	4
I	
Imuran	4
Influenza vaccine.....	5
Influvac	5
L	
Leflunomide	7
Levonorgestrel	6
Lodi	6
M	
Metronidazole	4
Modecate.....	4
MSUD Maxamaid	8
Mylan Clomiphen	6
N	
Naprosyn SR 750.....	7
Naprosyn SR 1000.....	7
Naproxen	7
P	
Piperacillin with tazobactam	4
Postinor-1.....	6
Prednisone.....	6
Prezista.....	6
Promod.....	8
Protein supplement	8
S	
Serophene	6
Sodium chloride.....	6
Sodium cromoglycate	4
Sumatriptan	7
T	
Tarceva.....	8
Tazocin EF.....	4
V	
Venlafaxine	7
W	
Water.....	6
Z	
Zyban	7



Email: enquiry@pharmac.govt.nz

www.pharmac.govt.nz/medicines/hospital-pharmaceuticals

Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand
Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz

ISSN 1179-3694 (Print) - ISSN 1179-3708 (Online)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.

If Undelivered, Return To: PO Box 10254, Wellington 6143, New Zealand